❖ Gao Yang, chairman of Berry Gene: The market space for assisted reproduction will continue to improve "carrier screening" is expected to become the next flashpoint
Recently, Gao Yang, chairman and general manager of Berry Gene, was interviewed by a reporter from the Financial Associated Press. In an interview, Gao Yang said that with everyone's emphasis on the quality of assisted reproduction, the market space such as genetic testing in the third generation of assisted reproductive technology is expected to increase. In the field of assisted reproduction, the genetic testing market for parents is expected to become the next flashpoint; however, the third generation of assisted reproductive technology faces problems on the supply side, and the entire market has not yet formed a scale. (Financial Associated Press)
❖ Nuoweizan signed a 224 million yuan equipment procurement contract
Recently, Novizon announced that Nanjing Novizan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company, and a domestic manufacturing automation equipment production enterprise recently signed three equipment procurement contracts, with a total amount of 224 million yuan. The subject of the three equipment procurement contracts is the fully automatic production and assembly equipment of the inspection card. The counterparty to the contract has been engaged in the development, production and manufacturing of automated production equipment and peripheral parts for many years, and has more than ten years of experience in the in vitro diagnostic production equipment industry, and its main customers include a number of large enterprises in the in vitro diagnostic reagent industry. in Gronhui
❖ The NGS detection kit for burning stone medicine tumors was approved by THE NMPA
On March 14, Lithologic Medicine announced that the State Drug Administration officially approved the registration of the company's "Human 9 Gene Mutation Combined Detection Kit (Reversible End Termination Sequencing Method)" (trade name "Lithosian Langke ™CDx") for the registration of three types of medical device products. The kit is the second multigenic tumor mutation combination assay approved by Litonecham Medicine based on Next Generation Sequencing and meeting the accompanying diagnostic criteria for in vitro detection of multiple variant states of EGFR, MET, ERBB2, KRAS, BRAF, PIK3CA, ALK, ROS1 and RET genes in patients with non-small cell lung cancer, including point mutations, insertion deletions, fusion (rearrangement) and amplification. Comprehensive guidance on targeted drug regimens for non-small cell lung cancer. (Company Announcement)
❖ Novartis SMA Gene Therapy Zolgensma's latest clinical results were announced to improve multiple indicators in children
On March 15, Novartis released the latest data from the Zolgensma (onasemnogene abeparvovec) clinical trial. The press release notes that Zolgensma is the first gene therapy approved for the treatment of spinal muscular atrophy (SMA) designed to stop disease progression with a single dose. The results of a Phase III clinical trial showed that children with 3 copies of the SMN2 gene who were treated prior to the onset of symptoms reached age-appropriate motor milestones, including standing and walking, did not require ventilation or feeding tube support, and had no serious, treatment-related adverse events. (Shenghui)
❖ FDA publishes draft guidelines for genome editing products
On March 16, the U.S. FDA released a draft guidance on how human gene therapies using genome editing technology should be regulated. The draft mentions some of the safety risks of gene therapy and makes some regulatory recommendations, such as the need for long-term follow-up for at least 15 years.
❖ Mainland scientists have developed a "precision-robustness" gene route design principle
Recently, the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences, together with Peking University and the Institute of Microbiology of the Chinese Academy of Sciences, published an article in Nucleic Acids Research, proposing the design principle of "precision-robustness" of functional gene lines, and successfully confirming the feasibility of this design principle by taking the steady-state adaptive function as an example. (Ministry of Science and Technology website)
Cancer Research: Exploring new biomarkers of melanoma based on large-scale genome-wide methylation analysis
Recently, H. Florida A research team led by Dr. Xuefeng Wang of lee Moffitt Cancer Center and Research Institute has discovered new tumor diagnostic markers. Based on DNA methylation sequencing data, the research team analyzed three cis eQTM CpGs (cg07786657, cg12446199 and cg00027570) closely related to tumor immunolytic cell activity scores (CYT) and can be used as alternative biomarkers to monitor the prognosis and immune status of melanoma. The findings were published in the journal Cancer Research. (WuXi AppTec)
Cell: Combining proteome and exome techniques to build a transcription factor interaction map to reveal the genetic determinants of congenital heart disease
Recently, the joint research team of the United States Gladstone Institutes and other units published an article in Cell. By integrating proteomics and human genetics methods, the research team analyzed the protein interactors of endogenous GATA4 and TBX5 in human heart progenitor cells to identify and prioritize the detection of potential heart disease genes and CHD-related variants, revealing various aspects of cardiac gene regulation.
Blood Cancer Discovery: WGS, WES, and RNA-seq jointly map AML mutations in recurrent children to reveal new mutations at high risk of recurrence
Recently, jeffery Klco's research team at St. Jude's Children's Research Hospital in the United States published a research article in Blood Cancer Discovery. The research team performed genetic and transcriptional analysis of 136 cases of recurrent childhood AML, mapped AML mutations in recurrent children, and found previously unrecognized UBTF exon 13 tandem repeat (UBTF-TD) mutation types in 9% of recurrent AML cases, and looking for the presence of this mutation at the time of diagnosis helped identify patients at high risk of recurrence.
All reprinted articles in this number are for the purpose of transmitting more information, and clearly indicate the source and author, and media or individuals who do not wish to be reprinted can contact us, and we will delete them immediately. All articles represent the views of the author only and do not represent the position of the Party.